Taxes are unavoidable and they are getting increasingly hard to comply with. Vertex has a strong position in the enterprise segment. Future growth should come from up/cross-selling rather than ...

California-based Tensile Capital Management increased its position in Vertex by 160,559 shares in the third quarter. Despite the increase in shares, the position value fell by about $34.4 million from ...

As of February 13, 2023, the average one-year price target for Vertex Pharmaceuticals is $338.23. The forecasts range from a low of $282.80 to a high of $462.00. The average price target represents an ...

Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug. However, the big drugmaker had plenty of good news in its Q1 update, too.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...